KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients

BACKGROUND: In this study, we evaluated the possibility that KRAS mutational status might be predictive of oxaliplatin (OXA) efficacy. We also explored the role of excision repair cross complementing group-1 (ERCC-1). METHODS: Ninety anti-epidermal growth factor receptor-naive advanced colorectal ca...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Basso, M, Strippoli, A, Orlandi, A, Martini, M, Calegari, M A, Schinzari, G, Di Salvatore, M, Cenci, T, Cassano, A, Larocca, L M, Barone, C
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Molecular Diagnostics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553525/
https://ncbi.nlm.nih.gov/pubmed/23175150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.526
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados